Schwab, Annemarie
Siddiqui, Mohammad Aarif https://orcid.org/0000-0003-4308-3398
Ramesh, Vignesh
Gollavilli, Paradesi Naidu
Turtos, Adriana Martinez
Møller, Sarah Søgaard https://orcid.org/0009-0002-3196-9538
Pinna, Luisa
Havelund, Jesper F.
Rømer, Anne Mette A.
Ersan, Pelin Gülizar
Parma, Beatrice
Marschall, Sabine
Dettmer, Katja
Alhusayan, Mohammed
Bertoglio, Pietro
Querzoli, Giulia
Mielenz, Dirk https://orcid.org/0000-0002-1135-0642
Sahin, Ozgur
Færgeman, Nils J.
Asangani, Irfan A.
Ceppi, Paolo https://orcid.org/0000-0002-3632-8476
Funding for this research was provided by:
Deutsche Krebshilfe (70112536)
Novo Nordisk Fonden (0066909)
Kræftens Bekæmpelse (A18859)
Lundbeckfonden (R380-2021-1264)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA249210)
U.S. Department of Defense (W81XWH-17-0404)
Det Frie Forskningsråd (2032-00062B)
Article History
Received: 25 April 2024
Revised: 4 November 2024
Accepted: 11 November 2024
First Online: 20 November 2024
Competing interests
: OS is the co-founder and manager of OncoCube Therapeutics LLC, founder, and president of LoxiGen, and the member of scientific advisory board of A2A Pharmaceuticals Inc. The other authors declare no conflict of interests.